Toolkit helps BRCA carriers tell family about cancer risk
NCT ID NCT04428736
First seen Apr 23, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This study tested whether a 'Disclosure Toolkit' — including a family letter, chatbot, and website — helps people with BRCA gene mutations share their results with at-risk relatives. 52 participants used the toolkit, and researchers measured how many relatives learned about the risk and pursued genetic testing. The goal is to improve family communication and early cancer prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Disclosure Toolkit (family letter, chatbot, website)
What this could lead to
If successful, this toolkit could help more at-risk relatives learn about their genetic risks and pursue testing, potentially preventing cancer through early action.
What could go wrong
This is a small, completed study with only 52 participants, so results may not apply to everyone. The toolkit's effectiveness depends on family dynamics and willingness to share.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.